BioCentury | Feb 18, 2020
Product Development

Riptide peptide turns TAMs proinflammatory

Riptide has lifted the curtain on its first immuno-oncology program, RP-182, which comprises an engineered peptide that reprograms tumor-associated macrophages to become proinflammatory. Strategies to convert immunosuppressive macrophages into proinflammatory cells have been gaining momentum...
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

Revolution’s first day performance suggests appetite for new biotech listings continues unabated in 2020, as investors’ demand for the cancer company’s shares rose both before and after its offering priced. Revolution Medicines Inc. (NASDAQ:RVMD) raised...
BioCentury | Feb 12, 2020
Product Development

Feb. 11 Product Development Quick Takes: J&J gets BARDA funding for COVID-19 vaccine; plus Novartis-Incyte, LogicBio and Elicio-Natera

BARDA to support Janssen COVID-19 vaccine R&D Johnson & Johnson (NYSE:JNJ) announced a collaboration with HHS that will speed development of a clinical COVID-19 (2019-nCoV) vaccine by its Janssen Pharmaceutical unit. The Biomedical Advanced Research...
BioCentury | Feb 1, 2020
Tools & Techniques

Rosenberg study opens wider door to personalized TCR therapies for cancer

A new study from TIL pioneer Steve Rosenberg adds to the momentum of personalized T cell therapies by suggesting blood can be as good a source of neoantigen-specific TCRs as tumor tissue. The results, which...
BC Extra | Jan 29, 2020
Preclinical News

Rosenberg study highlights opportunity for blood-based take on TILs against mutant p53

A new study from TIL pioneer Steve Rosenberg adds to the momentum of blood-derived personalized T cell therapies by showing concordance between T cell responses against common p53 mutations in patients’ solid tumors and those...
BC Extra | Jan 23, 2020
Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

Final sales milestone for Darzalex awards Genmab $150M under J&J deal  Genmab A/S (CSE:GMAB; NASDAQ:GMAB) will receive $150 million from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) after 2019 sales of multiple...
BC Extra | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

Schrödinger seeking NASDAQ listing  Computational physics and drug discovery company Schrödinger Inc. proposed to raise up to $100 million in an IPO on NASDAQ. The company’s largest shareholders are the Bill and Melinda Gates Foundation...
BC Extra | Jan 13, 2020
Company News

Jan. 13 Company Quick Takes: AZ ends fish oil trial; plus Lynparza, Lilly-NextCure, Innovent, Amgen-Qiagen-Guardant, Axsome-Pfizer

AstraZeneca ends CV outcomes trial of Epanova  AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued the Phase III STRENGTH trial after an IDMC determined it is unlikely to show that Epanova improved cardiovascular outcomes in patients with mixed...
BioCentury | Jan 11, 2020
Targets & Mechanisms

Colitis-associated somatic mutations yield new colorectal cancer target

Kyoto University team identifies colitis-associated somatic mutations that are lost in colitis-associated cancer to reveal a new colorectal cancer target. A Japanese team has identified novel colorectal cancer targets by contrasting somatic mutations in cancerous...
BioCentury | Jan 9, 2020
Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex...
Items per page:
1 - 10 of 1153